

Table 6. Prevalence of CAD in selected HFPEF studies

Study	Year	Setting	EF (%)	n	% with CAD
CHARM-Preserved	2003	Prospective randomized double-blinded trial	>40%	3023	56%
PEP-CHF	2006	Prospective randomized double-blinded trial	>40%	850	27%
I-PRESERVE	2008	Prospective randomized double-blinded trial	>45%	4128	25%
OPTIMIZE-HF	2009	National registry + Medicare data	≥40%	4153	35%